March 2, 2023
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, Massachusetts 02451
| Re: | Xilio Therapeutics, Inc. 2021 Stock Incentive Plan Xilio Therapeutics, Inc. 2021 Employee Stock Purchase Plan Xilio Therapeutics, Inc. 2022 Inducement Stock Incentive Plan |
Ladies and Gentlemen:
We have assisted in the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 1,923,296 shares of common stock, $0.0001 par value per share (the “Shares”), of Xilio Therapeutics, Inc., a Delaware corporation (the “Company”), of which (i) 1,373,580 shares are issuable under the Company’s 2021 Stock Incentive Plan (the “SIP”), (ii) 274,716 shares are issuable under the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”), and (iii) 275,000 shares are issuable under the Company’s 2022 Inducement Stock Incentive Plan (the “ISIP,” and, together with the SIP and the ESPP, the “Plans”).
We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement, the Plans and such other documents relating to the Company as we have deemed material for the purposes of this opinion.
In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the